Bay Area’s TriVascular Tech Nabs $10 Million, Launches EVAR Study in Women

Trivascular Technologies (NSDQ:TRIV) said it raised a $10 million funding round and launched a clinical study of endovascular aortic repair in women using its Ovation stent graft.

Santa Rosa, Calif.-based TriVascular said in a regulatory filing that it raised $10 million from 5 unnamed investors in a debt-and-warrants offering. The company, which won pre-market approval from the FDA this month for its Ovation iX device, raised $78 million in April 2014 with an initial public offering.

Help employers find you! Check out all the jobs and post your resume.
MORE ON THIS TOPIC